FDA-Approved Drugs Show Antiviral Activity Against MERS-CoV
This technology involves the screening of a library of 290 FDA-approved or clinically advanced compounds for their antiviral activity against Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). The screening identified 27 compounds with dual antiviral activity against both viruses, belonging to thirteen different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptors used as antipsychotics.